{"id":139,"date":"2026-01-30T10:32:10","date_gmt":"2026-01-30T09:32:10","guid":{"rendered":"https:\/\/serenada-alzheimer.info\/?page_id=139"},"modified":"2026-02-09T14:33:44","modified_gmt":"2026-02-09T13:33:44","slug":"politica-de-acceso-ampliado","status":"publish","type":"page","link":"https:\/\/serenada-alzheimer.info\/es\/expanded-access-policy\/","title":{"rendered":"Pol\u00edtica de Acceso Ampliado"},"content":{"rendered":"<div class=\"wp-block-group style-legal has-accent-1-color has-text-color has-link-color has-medium-font-size wp-elements-1 has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading\">Pol\u00edtica de acceso expandido<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Exciva est\u00e1 desarrollando actualmente un producto en investigaci\u00f3n (EXV-802) como posible tratamiento para la agitaci\u00f3n en personas con la enfermedad de Alzheimer. Exciva comprende que puede haber personas interesadas en acceder a EXV-802 fuera de un ensayo cl\u00ednico. En esta etapa de desarrollo, la \u00fanica forma de acceder a EXV-802 es participando en un estudio cl\u00ednico.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Exciva se compromete a apoyar a las personas con la enfermedad de Alzheimer que sufren de agitaci\u00f3n y a sus familias, con el objetivo de obtener la aprobaci\u00f3n regulatoria para brindar acceso al mayor n\u00famero posible de personas que tengan m\u00e1s probabilidades de beneficiarse. A medida que Exciva recopila m\u00e1s datos cl\u00ednicos sobre la seguridad y la eficacia de EXV-802, la empresa reconsiderar\u00e1 cuidadosamente la Pol\u00edtica de Acceso Ampliado seg\u00fan sea necesario para garantizar que est\u00e9 alineada con los mejores intereses de dichas personas.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Si tiene alguna pregunta sobre la Pol\u00edtica de Acceso Ampliado de Exciva, comun\u00edquese con&nbsp;<a href=\"mailto:studies@exciva.com\">studies@exciva.com<\/a>. Por favor, no nos env\u00ede ninguna informaci\u00f3n m\u00e9dica personal.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Expanded access policy Exciva is currently developing an investigational product (EXV-802) for potential treatment for agitation in people with Alzheimer\u2019s Disease. Exciva understands that there may be people who are interested in access to EXV-802 outside of a clinical trial. At this stage of development, the only way to gain access to EXV-802 is by [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-139","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/pages\/139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/comments?post=139"}],"version-history":[{"count":6,"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/pages\/139\/revisions"}],"predecessor-version":[{"id":291,"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/pages\/139\/revisions\/291"}],"wp:attachment":[{"href":"https:\/\/serenada-alzheimer.info\/es\/wp-json\/wp\/v2\/media?parent=139"}],"curies":[{"name":"bien jugado","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}